Quick Answer
Akebia Therapeutics, Inc. reported R&D Expense of $62.36 million for fiscal year 2025.
Akebia Therapeutics, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $62.36M | +65.6% |
| 2024 | $37.65M | -40.3% |
| 2023 | $63.08M | -51.5% |
| 2022 | $129.99M | -12.1% |
| 2021 | $147.85M | -32.3% |
| 2020 | $218.49M | -32.4% |
| 2019 | $322.97M | +11.0% |
| 2018 | $291.01M | +26.0% |
| 2017 | $230.89M | +99.4% |
| 2016 | $115.78M | +169.2% |
| 2015 | $43.02M | +84.9% |
| 2014 | $23.26M | +161.3% |
| 2013 | $8.90M | +58.1% |
| 2012 | $5.63M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $14.94M | +76.1% | +35.7% |
| June 30, 2025 | $11.01M | +44.0% | +12.9% |
| March 31, 2025 | $9.75M | +0.2% | +14.9% |
| September 30, 2024 | $8.49M | -36.3% | +11.0% |
| June 30, 2024 | $7.65M | -62.1% | -21.4% |
| March 31, 2024 | $9.73M | -50.6% | -27.0% |
| September 30, 2023 | $13.33M | -52.4% | -34.0% |
| June 30, 2023 | $20.20M | -22.4% | +2.6% |
- Akebia Therapeutics, Inc. showed an increase of +65.6% in R&D Expense compared to the prior fiscal year.
- Over the 2012–2025 period, Akebia Therapeutics, Inc.’s r&d expense has grown by 1007.2% (from $5.63 million to $62.36 million).
- The most recent figure is from Akebia Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: